At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,224 enrolled
Drug / intervention
80 mg ixekizumab Dosing Regimen +2 moredrug
Likely dose
80 mg ixekizumab Dosing Regimenfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
In Brief
A Phase 3 clinical trial evaluating 80 mg ixekizumab Dosing Regimen, 50 mg etanercept, and 1 other intervention for Psoriasis. Completed, enrolled 1,224 participants across 118 sites in 12 countries.
Detailed Summary
This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesAustralia, Austria, Canada, Czechia, France, Germany, Netherlands, Poland, Romania, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 2012
Enrollment StartMay 2012
Primary CompletionMar 2014
Study CompletionJun 2019
TodayJul 2026
First PostedMay 14, 2012
Enrollment StartMay 18, 2012
Primary CompletionMar 25, 2014
Study CompletionJun 18, 2019
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 14.1 years ago
Interventions
80 mg ixekizumab Dosing Regimendrug
Administered SC
50 mg etanerceptdrug
Administered SC
Placebodrug
Administered SC